Patients with HFpEF and HFrEF have different clinical characteristics but similar prognosis: A retrospective cohort study

BMC Cardiovascular Disorders

Volumn 16, Issue 1, 2016, Pages

  Abebe, Tamrat Befekadu ^a   Gebreyohannes, Eyob Alemayehu ^a   Tefera, Yonas Getaye ^a   Abegaz, Tadesse Melaku ^a  

^a UNIVERSITY OF GONDAR   (Ethiopia)

Author keywords

Clinical characteristics; Ejection fraction; Ethiopia; Heart failure; Survival

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SODIUM; SPIRONOLACTONE;

ADULT; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC DYSFUNCTION; ETHIOPIAN; FEMALE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SODIUM BLOOD LEVEL; SURVIVAL RATE; SYSTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; EPIDEMIOLOGY; ETHIOPIA; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; TIME FACTOR; TRENDS;

ECHOCARDIOGRAPHY; ETHIOPIA; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; STROKE VOLUME; SURVIVAL RATE; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 84997246197     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/s12872-016-0418-9     Document Type: Article

References (43)

1. van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016;18(3):242-52.
2. Sayago-Silva I, Garcia-Lopez F, Segovia-Cubero J. Epidemiology of heart failure in Spain over the last 20 years. Rev Esp Cardiol (English ed). 2013;66(8):649-56.
3. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137-46.
4. Anguita Sanchez M, Crespo Leiro MG, de Teresa GE, Jimenez Navarro M, Alonso-Pulpon L, Muniz GJ. Prevalence of heart failure in the Spanish general population aged over 45 years. The PRICE Study. Rev Esp Cardiol. 2008;61(10):1041-9.
5. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J. 1997;133(6):703-12.
6. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803-69.
7. Ntusi NB, Mayosi BM. Epidemiology of heart failure in sub-Saharan Africa. Expert Rev Cardiovasc Ther. 2009;7(2):169-80.
8. Parry EH. Diagnosis and management of heart failure in the young adult African. Br Med J. 1966;2(5522):1119-22.
9. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart. 2000;83(5):596-602.
10. Robert ND. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012;33(14):1750-7.
11. Lam CS, Solomon SD. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur J Heart Fail. 2014;16(10):1049-55.
12. Kindermann M. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28(21):2686. author reply -7.
13. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251-9.
14. Abhayaratna WP, Marwick TH, Smith WT, Becker NG. Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey. Heart. 2006;92(9):1259-64.
15. Fischer M, Baessler A, Hense HW, Hengstenberg C, Muscholl M, Holmer S, et al. Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J. 2003;24(4):320-8.
16. Klapholz M, Maurer M, Lowe AM, Messineo F, Meisner JS, Mitchell J, et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol. 2004;43(8):1432-8.
17. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47(1):76-84.
18. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768-77.
19. Macin SM, Perna ER, Cimbaro Canella JP, Alvarenga P, Pantich R, Rios N, et al. Differences in clinical profile and outcome in patients with decompensated heart failure and systolic dysfunction or preserved systolic function. Rev Esp Cardiol. 2004;57(1):45-52.
20. Martinez-Brana L, Mateo-Mosquera L, Bermudez-Ramos M, Valcarcel Garcia Mde L, Fernandez Hernandez L, Hermida Ameijeiras A, et al. Clinical characteristics and prognosis of heart failure in elderly patients. Rev Port Cardiol. 2015;34(7-8):457-63.
21. Somaratne JB, Berry C, McMurray JJ, Poppe KK, Doughty RN, Whalley GA. The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. Eur J Heart Fail. 2009;11(9):855-62.
22. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355(3):260-9.
23. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292(3):344-50.
24. Mori Y, Nishikawa Y, Kobayashi F, Hiramatsu K. Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol. Int Heart J. 2013;54(1):15-22.
25. Ho JE, Gona P, Pencina MJ, Tu JV, Austin PC, Vasan RS, et al. Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. Eur Heart J. 2012;33(14):1734-41.
26. Ojeda S, Anguita M, Munoz JF, Rodriguez MT, Mesa D, Franco M, et al. Clinical characteristics and medium-term prognosis of patients with heart failure and preserved systolic function. Do they differ in systolic dysfunction? Rev Esp Cardiol. 2003;56(11):1050-6.
27. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al. Relation of disease etiology and risk factors to heart failure with preserved or reduced ejection fraction: insights from the national heart, lung, and blood institute's Framingham heart study. Circulation. 2009;119(24):3070-7.
28. Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. Anemia and heart failure: a community study. Am J Med. 2008;121(8):726-32.
29. Punnoose LR, Givertz MM, Lewis EF, Pratibhu P, Stevenson LW, Desai AS. Heart failure with recovered ejection fraction: a distinct clinical entity. J Card Fail. 2011;17(7):527-32.
30. Elshaer F, Hassan W, Fawzy ME, Lockyer M, Kharabsheh S, Akhras N, et al. The prevalence, clinical characteristics, and prognosis of diastolic heart failure: a clinical study in elderly Saudi patients with up to 5 years follow-up. Congest Heart Fail (Greenwich, Conn). 2009;15(3):117-22.
31. Kaneko H, Suzuki S, Yajima J, Oikawa Y, Sagara K, Otsuka T, et al. Clinical characteristics and long-term clinical outcomes of Japanese heart failure patients with preserved versus reduced left ventricular ejection fraction: a prospective cohort of Shinken Database 2004-2011. J Cardiol. 2013;62(2):102-9.
32. Magana-Serrano JA, Almahmeed W, Gomez E, Al-Shamiri M, Adgar D, Sosner P, et al. Prevalence of heart failure with preserved ejection fraction in Latin American, Middle Eastern, and North African Regions in the I PREFER study (Identification of Patients With Heart Failure and PREserved Systolic Function: an epidemiological regional study). Am J Cardiol. 2011;108(9):1289-96.
33. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456-67.
34. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (London, England). 2003;362(9386):777-81.
35. Edelmann F, Stahrenberg R, Gelbrich G, Durstewitz K, Angermann CE, Dungen HD, et al. Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol. 2011;100(9):755-64.
36. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59(11):998-1005.
37. Varela-Roman A, Gonzalez-Juanatey JR, Basante P, Trillo R, Garcia-Seara J, Martinez-Sande JL, et al. Clinical characteristics and prognosis of hospitalised inpatients with heart failure and preserved or reduced left ventricular ejection fraction. Heart. 2002;88(3):249-54.
38. Juilliere Y, Suty-Selton C, Riant E, Darracq JP, Dellinger A, Labarre JP, et al. Prescription of cardiovascular drugs in the French ODIN cohort of heart failure patients according to age and type of chronic heart failure. Arch Cardiovasc Dis. 2014;107(1):21-32.
39. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2015;37(27):ehw128.
40. Kitzman DW, Hundley WG, Brubaker PH, Morgan TM, Moore JB, Stewart KP, et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail. 2010;3(4):477-85.
41. Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J. 2013;34(19):1424-31.
42. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-17.
43. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293-302.